1.1 Research Scope |
1.2 Market Segmentation |
1.3 Research Objectives |
1.4 Research Methodology |
| 1.4.1 Research Process |
| 1.4.2 Data Triangulation |
| 1.4.3 Research Approach |
| 1.4.4 Base Year |
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth |
| 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections |
| 1.5.2 Covid-19 Impact: Commodity Prices Indices |
| 1.5.3 Covid-19 Impact: Global Major Government Policy |
1.6 The Covid-19 Impact on IBS-C Drugs Industry |
1.7 COVID-19 Impact: IBS-C Drugs Market Trends |
2 Global IBS-C Drugs Quarterly Market Size Analysis |
2.1 IBS-C Drugs Business Impact Assessment - COVID-19 |
| 2.1.1 Global IBS-C Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 |
2.2 Global IBS-C Drugs Quarterly Market Size 2020-2021 |
2.3 COVID-19-Driven Market Dynamics and Factor Analysis |
| 2.3.1 Drivers |
| 2.3.2 Restraints |
| 2.3.3 Opportunities |
| 2.3.4 Challenges |
3 Quarterly Competitive Assessment, 2020 |
3.1 By Players, Global IBS-C Drugs Quarterly Market Size, 2019 VS 2020 |
3.2 By Players, IBS-C Drugs Headquarters and Area Served |
3.3 Date of Key Players Enter into IBS-C Drugs Market |
3.4 Key Players IBS-C Drugs Product Offered |
3.5 Mergers & Acquisitions, Expansion Plans |
4 Impact of Covid-19 on IBS-C Drugs Segments, By Type |
4.1 Introduction |
| 1.4.1 Linaclotide |
| 1.4.2 Lubiprostone |
| 1.4.3 Osmotic Laxatives |
| 1.4.4 Stimulant Laxatives |
| 1.4.5 Other |
| 轉~自：http://www.qdlaimaiche.com/7/10/Global-IBS-C-Drugs-Market-Analysis-and-Trends-Forecast-Report-2020-2026.html |
4.2 By Type, Global IBS-C Drugs Market Size, 2019-2021 |
5 Impact of Covid-19 on IBS-C Drugs Segments, By Application |
5.1 Overview |
| 5.5.1 Hospital Pharmacies |
| 5.5.2 Retail Pharmacies |
| 5.5.3 Online Pharmacies |
5.2 By Application, Global IBS-C Drugs Market Size, 2019-2021 |
| 5.2.1 By Application, Global IBS-C Drugs Market Size by Application, 2019-2021 |
6 Geographic Analysis |
6.1 Introduction |
6.2 North America |
| 6.2.1 Macroeconomic Indicators of US |
| 6.2.2 US |
| 6.2.3 Canada |
6.3 Europe |
| 6.3.1 Macroeconomic Indicators of Europe |
| 6.3.2 Germany |
| 6.3.3 France |
| 6.3.4 UK |
| 6.3.5 Italy |
6.4 Asia-Pacific |
| 6.4.1 Macroeconomic Indicators of Asia-Pacific |
| 6.4.2 China |
| 6.4.3 Japan |
| 6.4.4 South Korea |
| 6.4.5 India |
| 6.4.6 ASEAN |
6.5 Rest of World |
| 6.5.1 Latin America |
| 6.5.2 Middle East and Africa |
7 Company Profiles |
7.1 Company 1 |
| 7.1.1 Company 1 Business Overview |
| 7.1.2 Company 1 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.1.3 Company 1 IBS-C Drugs Product Introduction |
| 7.1.4 Company 1 Response to COVID-19 and Related Developments |
7.2 Company 2 |
| 7.2.1 Company 2 Business Overview |
| 7.2.2 Company 2 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.2.3 Company 2 IBS-C Drugs Product Introduction |
| 7.2.4 Company 2 Response to COVID-19 and Related Developments |
7.3 Company 3 |
| 7.3.1 Company 3 Business Overview |
| 7.3.2 Company 3 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.3.3 Company 3 IBS-C Drugs Product Introduction |
| 7.3.4 Company 3 Response to COVID-19 and Related Developments |
7.4 Company 4 |
| 7.4.1 Company 4 Business Overview |
| 7.4.2 Company 4 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.4.3 Company 4 IBS-C Drugs Product Introduction |
| 7.4.4 Company 4 Response to COVID-19 and Related Developments |
7.5 Company 5 |
| 7.5.1 Company 5 Business Overview |
| 7.5.2 Company 5 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.5.3 Company 5 IBS-C Drugs Product Introduction |
| 7.5.4 Company 5 Response to COVID-19 and Related Developments |
7.6 Company 6 |
| 7.6.1 Company 6 Business Overview |
| 7.6.2 Company 6 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.6.3 Company 6 IBS-C Drugs Product Introduction |
| 7.6.4 Company 6 Response to COVID-19 and Related Developments |
7.7 Company 7 |
| 7.7.1 Company 7 Business Overview |
| 7.7.2 Company 7 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.7.3 Company 7 IBS-C Drugs Product Introduction |
| 7.7.4 Company 7 Response to COVID-19 and Related Developments |
7.8 Company 8 |
| 7.8.1 Company 8 Business Overview |
| 7.8.2 Company 8 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.8.3 Company 8 IBS-C Drugs Product Introduction |
| 7.8.4 Company 8 Response to COVID-19 and Related Developments |
7.9 Company 9 |
| 全球IBS-C藥物市場分析及趨勢預測報告二零二零年至2026年 |
| 7.9.1 Company 9 Business Overview |
| 7.9.2 Company 9 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.9.3 Company 9 IBS-C Drugs Product Introduction |
| 7.9.4 Company 9 Response to COVID-19 and Related Developments |
7.10 Company 10 |
| 7.10.1 Company 10 Business Overview |
| 7.10.2 Company 10 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.10.3 Company 10 IBS-C Drugs Product Introduction |
| 7.10.4 Company 10 Response to COVID-19 and Related Developments |
7.11 Company 11 |
| 7.11.1 Company 11 Business Overview |
| 7.11.2 Company 11 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.11.3 Company 11 IBS-C Drugs Product Introduction |
| 7.11.4 Company 11 Response to COVID-19 and Related Developments |
7.12 Company 12 |
| 7.12.1 Company 12 Business Overview |
| 7.12.2 Company 12 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.12.3 Company 12 IBS-C Drugs Product Introduction |
| 7.12.4 Company 12 Response to COVID-19 and Related Developments |
7.13 Company 13 |
| 7.13.1 Company 13 Business Overview |
| 7.13.2 Company 13 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.13.3 Company 13 IBS-C Drugs Product Introduction |
| 7.13.4 Company 13 Response to COVID-19 and Related Developments |
7.14 Company 14 |
| 7.14.1 Company 14 Business Overview |
| 7.14.2 Company 14 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.14.3 Company 14 IBS-C Drugs Product Introduction |
| 7.14.4 Company 14 Response to COVID-19 and Related Developments |
7.15 Company 15 |
| 7.15.1 Company 15 Business Overview |
| 7.15.2 Company 15 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.15.3 Company 15 IBS-C Drugs Product Introduction |
| 7.15.4 Company 15 Response to COVID-19 and Related Developments |
7.16 Company 16 |
| 7.16.1 Company 16 Business Overview |
| 7.16.2 Company 16 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.16.3 Company 16 IBS-C Drugs Product Introduction |
| 7.16.4 Company 16 Response to COVID-19 and Related Developments |
7.17 Company 17 |
| 7.17.1 Company 17 Business Overview |
| 7.17.2 Company 17 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.17.3 Company 17 IBS-C Drugs Product Introduction |
| 7.17.4 Company 17 Response to COVID-19 and Related Developments |
7.18 Company 18 |
| 7.18.1 Company 18 Business Overview |
| 7.18.2 Company 18 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.18.3 Company 18 IBS-C Drugs Product Introduction |
| 7.18.4 Company 18 Response to COVID-19 and Related Developments |
7.19 Company 19 |
| 7.19.1 Company 19 Business Overview |
| 7.19.2 Company 19 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.19.3 Company 19 IBS-C Drugs Product Introduction |
| 7.19.4 Company 19 Response to COVID-19 and Related Developments |
7.20 Company 20 |
| 7.20.1 Company 20 Business Overview |
| 7.20.2 Company 20 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.20.3 Company 20 IBS-C Drugs Product Introduction |
| 7.20.4 Company 20 Response to COVID-19 and Related Developments |
7.21 Company 21 |
| 7.21.1 Company 21 Business Overview |
| 7.21.2 Company 21 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.21.3 Company 21 IBS-C Drugs Product Introduction |
| 7.21.4 Company 21 Response to COVID-19 and Related Developments |
7.22 Company 22 |
| 7.22.1 Company 22 Business Overview |
| 7.22.2 Company 22 IBS-C Drugs Quarterly Revenue, 2020 |
| 7.22.3 Company 22 IBS-C Drugs Product Introduction |
| 7.22.4 Company 22 Response to COVID-19 and Related Developments |
8 Key Findings |
9 Appendix |
9.1 About US |
| 全球IBS-C藥物市場分析及趨勢預測報告二零二零年至2026年 |
9.2 Disclaimer |
| List of Tables |
| Table 1. Overview of the World Economic Outlook Projections |
| Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity) |
| Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) |
| Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) |
| Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) |
| Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise) |
| Table 7. Covid-19 Impact: Global Major Government Policy |
| Table 8. The Covid-19 Impact on IBS-C Drugs Assessment |
| Table 9. COVID-19 Impact: IBS-C Drugs Market Trends |
| Table 10. COVID-19 Impact Global IBS-C Drugs Market Size |
| Table 11. Global IBS-C Drugs Quarterly Market Size, 2020 (US$ Million) |
| Table 12. Global IBS-C Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million) |
| Table 13. Global IBS-C Drugs Market Growth Drivers |
| Table 14. Global IBS-C Drugs Market Restraints |
| Table 15. Global IBS-C Drugs Market Opportunities |
| Table 16. Global IBS-C Drugs Market Challenges |
| Table 17. By Players, IBS-C Drugs Quarterly Revenue, 2019 VS 2020 (US$ Million) |
| Table 18. Key Players, IBS-C Drugs Revenue Market Share, 2019 VS 2020 (%) |
| Table 19. Key IBS-C Drugs Players Headquarters and Area Served |
| Table 20. Date of Key Players Enter into IBS-C Drugs Market |
| Table 21. Key Players IBS-C Drugs Product Type |
| Table 22. Mergers & Acquisitions, Expansion Plans |
| Table 23. By Players, Global IBS-C Drugs Market Size 2019-2021, (US$ Million) |
| Table 24. Global IBS-C Drugs Market Size by Application: 2019-2021 (US$ Million) |
| Table 25. Global IBS-C Drugs Market Size by Region, 2019-2021 (US$ Million) |
| Table 26. By Country, North America IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 27. By Type, US IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 28. By Application, US IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 29. By Type, Canada IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 30. By Application, Canada IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 31. Macroeconomic Indicators of Europe (Germany, France, UK and Italy) |
| Table 32. By Country, Europe IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 33. By Type, Germany IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 34. By Application, Germany IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 35. By Type, France IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 36. By Application, France IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 37. By Type, UK IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 38. By Application, UK IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 39. By Type, Italy IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 40. By Application, Italy IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 41. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN) |
| Table 42. By Region, Asia-Pacific IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 43. By Type, China IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 44. By Application, China IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 45. By Type, Japan IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 46. By Application, Japan IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 47. By Type, South Korea IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 48. By Application, South Korea IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 49. By Type, India IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 50. By Application, India IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 51. By Type, ASEAN IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 52. By Application, ASEAN IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 53. By Type, Latin America IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 54. By Application, Latin America IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 55. By Type, Middle East and Africa IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 56. By Application, Middle East and Africa IBS-C Drugs Market Size, 2019-2021 (US$ Million) |
| Table 57. Company 1 Business Overview |
| Table 58. Company 1 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 59. Company 1 IBS-C Drugs Product |
| Table 60. Company 1 Response to COVID-19 and Related Developments |
| Table 61. Company 2 Business Overview |
| Table 62. Company 2 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 63. Company 2 IBS-C Drugs Product |
| Table 64. Company 2 Response to COVID-19 and Related Developments |
| Table 65. Company 3 Business Overview |
| Table 66. Company 3 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| quánqiú IBS-C yàowù shìchǎng fēnxī jí qūshì yùcè bàogào èr líng èr líng nián zhì 2026 nián |
| Table 67. Company 3 IBS-C Drugs Product |
| Table 68. Company 3 Response to COVID-19 and Related Developments |
| Table 69. Company 4 Business Overview |
| Table 70. Company 4 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 71. Company 4 IBS-C Drugs Product |
| Table 72. Company 4 Response to COVID-19 and Related Developments |
| Table 73. Company 5 Business Overview |
| Table 74. Company 5 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 75. Company 5 IBS-C Drugs Product |
| Table 76. Company 5 Response to COVID-19 and Related Developments |
| Table 77. Company 6 Business Overview |
| Table 78. Company 6 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 79. Company 6 IBS-C Drugs Product |
| Table 80. Company 6 Response to COVID-19 and Related Developments |
| Table 81. Company 7 Business Overview |
| Table 82. Company 7 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 83. Company 7 IBS-C Drugs Product |
| Table 84. Company 7 Response to COVID-19 and Related Developments |
| Table 85. Company 8 Business Overview |
| Table 86. Company 8 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 87. Company 8 IBS-C Drugs Product |
| Table 88. Company 8 Response to COVID-19 and Related Developments |
| Table 89. Company 9 Business Overview |
| Table 90. Company 9 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 91. Company 9 IBS-C Drugs Product |
| Table 92. Company 9 Response to COVID-19 and Related Developments |
| Table 93. Company 10 Business Overview |
| Table 94. Company 10 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 95. Company 10 IBS-C Drugs Product |
| Table 96. Company 10 Response to COVID-19 and Related Developments |
| Table 97. Company 11 Business Overview |
| Table 98. Company 11 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 99. Company 11 IBS-C Drugs Product |
| Table 100. Company 11 Response to COVID-19 and Related Developments |
| Table 101. Company 12 Business Overview |
| Table 102. Company 12 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 103. Company 12 IBS-C Drugs Product |
| Table 104. Company 12 Response to COVID-19 and Related Developments |
| Table 105. Company 13 Business Overview |
| Table 106. Company 13 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 107. Company 13 IBS-C Drugs Product |
| Table 108. Company 13 Response to COVID-19 and Related Developments |
| Table 109. Company 14 Business Overview |
| Table 110. Company 14 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 111. Company 14 IBS-C Drugs Product |
| Table 112. Company 14 Response to COVID-19 and Related Developments |
| Table 113. Company 15 Business Overview |
| Table 114. Company 15 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 115. Company 15 IBS-C Drugs Product |
| Table 116. Company 15 Response to COVID-19 and Related Developments |
| Table 117. Company 16 Business Overview |
| Table 118. Company 16 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 119. Company 16 IBS-C Drugs Product |
| Table 120. Company 16 Response to COVID-19 and Related Developments |
| Table 121. Company 17 Business Overview |
| Table 122. Company 17 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 123. Company 17 IBS-C Drugs Product |
| Table 124. Company 17 Response to COVID-19 and Related Developments |
| Table 125. Company 18 Business Overview |
| Table 126. Company 18 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 127. Company 18 IBS-C Drugs Product |
| Table 128. Company 18 Response to COVID-19 and Related Developments |
| Table 129. Company 19 Business Overview |
| Table 130. Company 19 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 131. Company 19 IBS-C Drugs Product |
| Table 132. Company 19 Response to COVID-19 and Related Developments |
| Table 133. Company 20 Business Overview |
| Table 134. Company 20 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 135. Company 20 IBS-C Drugs Product |
| Table 136. Company 20 Response to COVID-19 and Related Developments |
| Table 137. Company 21 Business Overview |
| グローバルIBS-C薬市場の分析と動向予測レポート2020-2026 |
| Table 138. Company 21 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 139. Company 21 IBS-C Drugs Product |
| Table 140. Company 21 Response to COVID-19 and Related Developments |
| Table 141. Company 22 Business Overview |
| Table 142. Company 22 IBS-C Drugs Revenue (US$ Million), (Q1, Q2, Q3, Q4) Quarter 2020 |
| Table 143. Company 22 IBS-C Drugs Product |
| Table 144. Company 22 Response to COVID-19 and Related Developments |
| List of Figures |
| Figure 1. IBS-C Drugs Product Picture |
| Figure 2. IBS-C Drugs Market Segmentation |
| Figure 3. Research Objectives |
| Figure 4. Research Process |
| Figure 5. Data Triangulation |
| Figure 6. Research Approach |
| Figure 7. Commodity Prices-Metals Price Indices |
| Figure 8. Commodity Prices- Precious Metal Price Indices |
| Figure 9. Commodity Prices- Agricultural Raw Material Price Indices |
| Figure 10. Commodity Prices- Food and Beverage Price Indices |
| Figure 11. Commodity Prices- Fertilizer Price Indices |
| Figure 12. Commodity Prices- Energy Price Indices |
| Figure 13. G20+: Economic Policy Responses to COVID-19 |
| Figure 14. Global IBS-C Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million) |
| Figure 15. Global IBS-C Drugs Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%) |
| Figure 16. Global IBS-C Drugs Market Size, Quarterly Growth, 2020-2021 (%) |
| Figure 17. Global IBS-C Drugs Market Size, Market Share by Type, 2019 VS 2020 (%) |
| Figure 18. Global IBS-C Drugs Market Size, Market Share by Application, 2019 VS 2020 (%) |
| Figure 19. Global IBS-C Drugs Market Size Market Share by Region, 2019 VS 2020 (%) |
| Figure 20. United States Composite PMI and GDP |
| Figure 21. Eurozone Composite PMI and GDP |
| Figure 22. Eurozone Core v. Periphery PMI Output Indices |
| Figure 23. Core v. Periphery PMI Employment Indices |
| Figure 24. UK Composite PMI and GDP |
| Figure 25. Caixin China Composite Output Index |
| Figure 26. Caixin China General Services Business Activity Index |
| Figure 27. Japan Composite Output Index |
| Figure 28. South Korea Manufacturing PMI |
| Figure 29. India Composite Output Index |
| Figure 30. ASEAN Manufacturing PMI |
| Figure 31. By Region, Asia-Pacific IBS-C Drugs Market Size Market Share, 2019-2021 |
略……
如需購買《Global IBS-C Drugs Market Analysis and Trends Forecast Report 2020-2026》，編號：2806107
請您致電：400 612 8668、010-6618 1099、66182099、66183099
或Email至：KF@Cir.cn 【網上訂購】 ┊ 下載《訂購協議》 ┊ 了解“訂購流程”
請您致電：400 612 8668、010-6618 1099、66182099、66183099
或Email至：KF@Cir.cn 【網上訂購】 ┊ 下載《訂購協議》 ┊ 了解“訂購流程”
京公網安備 11010802027365號